Alhejaili Asrar L, Alkayyal Aaesha A, Alawaz Razan A, Alshareef Esraa K, Al-Habboubi Hussain
Pediatric Ophthalmology, King Abdullah Specialist Children's Hospital, Riyadh, SAU.
Internal Medicine, Saudi German Hospital, Medina, SAU.
Cureus. 2024 Oct 11;16(10):e71271. doi: 10.7759/cureus.71271. eCollection 2024 Oct.
Botulinum toxin type A (BTXA) is a well-accepted non-surgical therapy for strabismus. However, its dose and technique vary widely. We reviewed published evidence on the dose effect of BTXA in treating various types of strabismus. Articles on BTXA therapy outcomes were reviewed to study doses and brands of BTXA used and their efficacy for specific types of strabismus. Researchers indicated that greater dosages may be used safely without increasing the risk of complications. The review suggested a positive dose-response relationship of BTX to success but with a higher risk of complications. No single dose of BTX could be recommended for strabismus management.
A型肉毒杆菌毒素(BTXA)是一种广泛认可的用于治疗斜视的非手术疗法。然而,其剂量和技术差异很大。我们回顾了已发表的关于BTXA治疗各种类型斜视剂量效应的证据。对有关BTXA治疗结果的文章进行了综述,以研究所用BTXA的剂量、品牌及其对特定类型斜视的疗效。研究人员指出,可以安全地使用更大剂量,而不会增加并发症的风险。该综述表明BTX与治疗成功之间存在正剂量反应关系,但并发症风险较高。对于斜视治疗,无法推荐单一剂量的BTX。